Please assess the completion status of the following clinical trial:

Trial Title: Cardiovascular Improvements With MV ASV Therapy in Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients 21 years or older~* Patients with prior clinical diagnosis of heart failure (HFrEF or HFpEF), or de novo diagnosis of HFpEF indicated by a local BNP≥300 pg/mL or NT pro-BNP≥1200 pg/mL on admission without systolic blood pressure \>180 mmHg or atrial fibrillation, or diagnosis of HFrEF indicated by documented evidence of prescribed beta-blockers and ACE-inhibitors or ARBs for at least 4 weeks prior to admission~* Hospital admission for acute decompensated HF as determined by:~  * Dyspnea at rest or with minimal exertion~    * AND At least two of the following signs and symptoms:~ * Orthopnea~ * Pulmonary rales beyond basilar~ * Chest congestion on x-ray~ * BNP≥300pg/mL or NT pro-BNP≥1200pg/mL~ * Pulmonary capillary wedge pressure (PCWP) ≥25mmHg during current hospitalization~* Presented to hospital or clinic at least 24 hours prior to consent~* Patient stable enough to stop oxygen use for duration of polygraphy test or have access to dual lumen cannula for polygraphy test~* Sleep disordered breathing (SDB) documented by polygraphy with an AHI≥15 events/hour~* Patient is able to fully understand study information and sign a consent form~Exclusion Criteria:~* Right-sided heart failure without left-sided heart failure~* Sustained systolic blood pressure \<80 mmHg at baseline~* Acute coronary syndrome within 1 months of randomization~* Active myocarditis~* Complex congenital heart disease~* Constrictive pericarditis~* Non-cardiac pulmonary edema~* Clinical evidence of digoxin toxicity~* Need for mechanical hemodynamic support at time of randomization~* Oxygen saturation ≤85% at rest during the day or at start of nocturnal oximetry recording or regular use of oxygen therapy (day or night)~* COPD exacerbation as the primary reason for hospital admission~* Current use (within 4 weeks of study entry) of any PAP-therapy (eg, fixed, bi-level, or APAP)~* Life expectancy \< 1 year for diseases unrelated to HF~* Transient ischemic attack (TIA) or Stroke within 3 months prior to randomization~* CABG procedure within 3 months prior to randomization, or planned to occur during study period~* CRT implant within 3 months prior to randomization , or planned to occur during study period~* VAD implant planned to occur during study period~* Heart transplant list Status 1a or 1b~* Status post-transplant or LVAD~* Prescribed inotrope therapy anticipated at discharge~* Chronic Dialysis~* Known amyloidosis, hypertrophic obstructive cardiomyopathy, arteriovenous fistulas~* Primary hemodynamically significant uncorrected valvular heart disease (obstructive or regurgitant) with planned intervention within 6 months of randomization~* Pregnant, or planning to become pregnant~* Cannot tolerate ASV treatment during run-in~* Cannot perform 6MWT at baseline~* Occupation as a commercial driver or pilot and plan to be performing these activities during the study period~* Inability to comply with planned study procedures~* Participation in pharmaceutical or treatment-related clinical study within 1 month of study enrollment

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MV ASV+OMT (Type: EXPERIMENTAL): Minute Ventilation-targeted adaptive servo-ventilation therapy plus optimized medical treatment
- OMT only (Type: ACTIVE_COMPARATOR): Optimized Medical Treatment for heart failure in accordance with applicable guidelines (ACCF/AHA Guideline for the Management of Heart Failure and HFSA Heart Failure Guidelines.

Based on this trial design, predict the completion outcome and termination type (if applicable).